Pfenex Inc (NYSEMKT:PFNX)‘s stock had its “outperform” rating reaffirmed by research analysts at William Blair in a research note issued to investors on Thursday.
PFNX has been the subject of several other research reports. Zacks Investment Research upgraded shares of Pfenex from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research report on Wednesday, July 19th. ValuEngine lowered shares of Pfenex from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st.
Shares of Pfenex (PFNX) opened at 3.90 on Thursday. Pfenex has a 1-year low of $3.54 and a 1-year high of $11.35. The firm has a 50-day moving average of $4.31 and a 200 day moving average of $5.42. The company has a market capitalization of $91.47 million, a P/E ratio of 25.49 and a beta of 4.65.
Pfenex (NYSEMKT:PFNX) last released its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by $0.06. Pfenex had a negative net margin of 356.00% and a negative return on equity of 53.20%. The business had revenue of $3.03 million for the quarter, compared to the consensus estimate of $3.10 million. During the same quarter last year, the business earned ($0.43) EPS. Pfenex’s revenue for the quarter was down 3.5% compared to the same quarter last year. On average, analysts anticipate that Pfenex will post ($2.09) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Pfenex Inc (NYSEMKT:PFNX) Rating Reiterated by William Blair” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/12/pfenex-inc-nysemktpfnx-rating-reiterated-by-william-blair.html.
In other news, Director Jason Grenfell-Gardner bought 10,000 shares of the stock in a transaction dated Monday, June 12th. The stock was purchased at an average price of $4.51 per share, for a total transaction of $45,100.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $45,100. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
A number of large investors have recently made changes to their positions in PFNX. Russell Investments Group Ltd. raised its stake in shares of Pfenex by 221.0% in the first quarter. Russell Investments Group Ltd. now owns 32,186 shares of the biotechnology company’s stock worth $187,000 after buying an additional 22,160 shares during the last quarter. Algert Global LLC raised its stake in shares of Pfenex by 207.3% in the first quarter. Algert Global LLC now owns 34,603 shares of the biotechnology company’s stock worth $201,000 after buying an additional 23,344 shares during the last quarter. Nine Chapters Capital Management LLC bought a new stake in shares of Pfenex during the first quarter worth $265,000. Goldman Sachs Group Inc. raised its stake in shares of Pfenex by 126.7% in the first quarter. Goldman Sachs Group Inc. now owns 56,020 shares of the biotechnology company’s stock worth $325,000 after buying an additional 31,308 shares during the last quarter. Finally, LMR Partners LLP bought a new stake in shares of Pfenex during the second quarter worth $252,000.
Pfenex Company Profile
Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).
What are top analysts saying about Pfenex Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfenex Inc and related companies.